Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Termination of Translation01:44

Termination of Translation

The large ribosomal subunit has several important structures essential to translation. These include the peptidyl transferase center (PTC) - which is the site where the peptide bond is formed - and a large, internal, water-filled tube through which the nascent polypeptide moves. This latter structure is called the Peptide Exit Tunnel, and it begins at the PTC and spans the body of the large ribosomal subunit. During translation, as the nascent polypeptide chain is synthesized, it passes through...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Termination of Translation01:44

Termination of Translation

The large ribosomal subunit has several important structures essential to translation. These include the peptidyl transferase center (PTC) - which is the site where the peptide bond is formed - and a large, internal, water-filled tube through which the nascent polypeptide moves. This latter structure is called the Peptide Exit Tunnel, and it begins at the PTC and spans the body of the large ribosomal subunit. During translation, as the nascent polypeptide chain is synthesized, it passes through...
Translation01:31

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are called the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of digital tools and artificial intelligence in supporting antimicrobial stewardship: a systematic review.

The Journal of antimicrobial chemotherapy·2026
Same author

Effectiveness and safety of first-line nivolumab-ipilimumab in metastatic renal cell carcinoma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

The role of digital tools and artificial intelligence in supporting antimicrobial stewardship: Study protocol for a systematic review.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same author

Improvements in pharmacokinetics, bleeding control, and cost analysis after PK-guided transition to extended-half-life factor IX in hemophilia B: A multicentric study.

Thrombosis research·2026
Same author

Systemic metabolic reprogramming and microbial dysbiosis in Fabry disease: Multi-omics mechanisms and implications for drug development.

Frontiers in pharmacology·2026
Same author

The role of digital tools and artificial intelligence in supporting antimicrobial stewardship: Study protocol for a systematic review.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2025

Related Experiment Video

Updated: May 10, 2026

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow
08:54

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

1.7K

[Translated article] OrPhar-SEFH 2024-2027 Strategic Plan.

Mónica Climente Martí1, María Dolores Edo Solsona2, María Reyes Abad Sazatornil3

  • 1Servicio de Farmacia, Hospital Universitario Dr. Peset, Valencia, Spain.

Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|June 6, 2025
PubMed
Summary
This summary is machine-generated.

The OrPhar-SEFH Strategic Plan 2024-2027 outlines key actions to advance hospital pharmacy's role in rare disease care. It prioritizes collaboration, evidence analysis, and specialized services for orphan drugs and patient outcomes.

Keywords:
Análisis de decisión multicriterioEnfermedades rarasEquipos interdisciplinaresInterdisciplinary teamsMedicamentos huérfanosMulti-criteria decision analysisOrphan drugsPlan estratégicoRare diseasesStrategic plan

More Related Videos

Author Spotlight: Development of a Novel Finite Element Analysis Model for Improved Orthognathic Surgical Techniques
07:16

Author Spotlight: Development of a Novel Finite Element Analysis Model for Improved Orthognathic Surgical Techniques

Published on: October 20, 2023

1.4K
Scalable Step-by-Step Approach of Sustainable Bioplastic Production from Food Waste
08:14

Scalable Step-by-Step Approach of Sustainable Bioplastic Production from Food Waste

Published on: July 18, 2025

340

Related Experiment Videos

Last Updated: May 10, 2026

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow
08:54

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

1.7K
Author Spotlight: Development of a Novel Finite Element Analysis Model for Improved Orthognathic Surgical Techniques
07:16

Author Spotlight: Development of a Novel Finite Element Analysis Model for Improved Orthognathic Surgical Techniques

Published on: October 20, 2023

1.4K
Scalable Step-by-Step Approach of Sustainable Bioplastic Production from Food Waste
08:14

Scalable Step-by-Step Approach of Sustainable Bioplastic Production from Food Waste

Published on: July 18, 2025

340

Area of Science:

  • Pharmacology and Pharmaceutical Sciences
  • Health Services Research
  • Rare Disease Management

Background:

  • The landscape of rare diseases presents unique challenges for hospital pharmacy services.
  • Existing structures require transformation to effectively address the needs of patients with rare diseases and the complexities of orphan drug management.
  • The OrPhar-SEFH group recognized the need for a strategic plan to guide hospital pharmacists in this specialized area.

Purpose of the Study:

  • To develop the OrPhar-SEFH Strategic Plan 2024-2027, aiming to promote the transformation of hospital pharmacy in the field of rare diseases.
  • To identify key trends, challenges, and opportunities impacting hospital pharmacists and patients with rare diseases.
  • To define and prioritize actionable strategies to enhance the role of hospital pharmacists in rare disease care.

Main Methods:

  • A three-phase approach was employed: situation analysis (literature review, interviews, SWOT), definition of action lines (grouped into five strategic axes: Alliances, Evidence, Research/Innovation, Optimization, Union), and prioritization based on impact and feasibility.
  • Interviews were conducted with hospital pharmacists and patient advocacy groups (FundAME, Fedhemo) to gather diverse perspectives.
  • Analysis focused on four levers for change: care process transformation, patient experience, orphan drug evaluation/access, and real-world evidence.

Main Results:

  • A total of 23 lines of action were agreed upon across the five strategic axes.
  • Key prioritized actions include enhancing hospital pharmacist collaboration in orphan drug evaluation, strengthening critical analysis of scientific evidence, promoting Multi-Criteria Decision Analysis for orphan drugs, integrating pharmacists into interdisciplinary teams, and establishing a network of specialized services.
  • Patient interviews highlighted needs concerning the hospital pharmacist's role, patient experience, education, and treatment access.

Conclusions:

  • The OrPhar-SEFH Strategic Plan 2024-2027 provides a roadmap for hospital pharmacists to improve rare disease management.
  • The plan emphasizes enhancing the evaluation and access to orphan drugs, optimizing care processes, and improving patient outcomes and quality of life.
  • Strategic implementation is expected to significantly advance the hospital pharmacy's contribution to rare disease patient care.